Vaccines & Disease · Tetanus

Who should not get tetanus vaccine?

2 min read

The Institute of Medicine (IOM) has acknowledged that there is individual susceptibility to vaccine reactions for genetic, biological and environmental reasons, but that vaccine providers cannot accurately predict prior to a vaccine’s administration who will suffer complications, injury or death from vaccination. However, a person who has previously had a serious reaction to a vaccination or is acutely or chronically ill should become informed about all potential risks associated with vaccination and discuss any concerns with a trusted health care professional before receiving a DTaP/Tdap/Td vaccine or any other vaccine.

The tetanus toxoid vaccine is only available in combination with other routinely administered vaccines and is most frequently combined with diphtheria (DT, Td) and acellular pertussis vaccines (DTaP, Tdap). It is also found in combination with vaccines for polio, Haemophilus influenzae type b (Hib), and hepatitis B.

The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of all infants and young children with the combination diphtheria, tetanus, and acellular pertussis vaccine (DTaP) at 2, 4, 6, 15-18 months, and 4 to 6 years; however, children under the age of seven with a contraindication to pertussis vaccination are recommended to receive the diphtheria-tetanus toxoid vaccine (DT) in place of the pertussis-containing DTaP vaccine. In January 2023, Sanofi Pasteur announced that it had discontinued manufacturing of the DT vaccine. In February 2024, the CDC recommended that infants and children with a contraindication to acellular pertussis vaccine receive the tetanus-diphtheria (Td) vaccine in place of DTaP. Td vaccine is licensed for individuals seven years of age and older, and use of this vaccine in children under age seven is considered “off-label.”

According to the CDC, diphtheria, tetanus, and acellular pertussis vaccines (DTaP) should not be administered to any person who has experienced a severe allergic reaction to a previous dose or to anyone with a severe allergy to any ingredient found within the vaccine.

If a person has a previous health history of Guillain-Barré syndrome (GBS) within 6 weeks of receiving a dose of a tetanus toxoid-containing vaccine, or is considered moderately or severely ill, the CDC recommends that vaccination be given only if the potential benefits of vaccination outweigh the possible risks. As well, anyone who has experienced an Arthus-type hypersensitivity reaction following a previous dose of a diphtheria or tetanus toxoid-containing vaccine should not receive another tetanus-diphtheria (Td) vaccine more frequently than every 10 years.

Any person who developed encephalopathy within seven days of vaccination with a pertussis-containing vaccine (DTP, DTaP, Tdap) should not receive another pertussis-containing vaccine (DTaP, Tdap).

IMPORTANT NOTE: NVIC encourages you to become fully informed about Tetanus and the Tetanus vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.

Select disease / vaccine